Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

This study is testing whether donafenib — a targeted oral cancer drug — can help prevent liver cancer from recurring after ablation (tumor destruction) in patients whose liver cancer has already come back once or twice. Researchers want to see if giving this drug after ablation can delay or prevent another recurrence. **You may be eligible if...** - You are between 18 and 75 years old - Your liver cancer has recurred for the first or second time - The recurrent tumors are small enough to meet Milan criteria (a single tumor under 5 cm, or up to 3 tumors each under 3 cm) - Your cancer came back within the first year after initial treatment - You are not willing or eligible for repeat surgery or liver transplant - Your liver is still functioning well (Child-Pugh A or B) **You may NOT be eligible if...** - Your recurrent cancer exceeds Milan criteria in size or number - Your cancer has spread outside the liver - You have primary (first-time) liver cancer Talk to your doctor to see if this trial is right for you.